Co-payments in reform of German health system financing?
This article was originally published in Clinica
Executive Summary
Policies implemented by the German government, aimed at increasing efficiency and cutting costs in the health service, are having a profound effect on all healthcare industries. As interested parties jostle for position in the wake of the upheaval caused by the recent healthcare reforms, the medical technology industry association, BVMed, is increasingly determined to make its voice heard. It is up to the association's new chairman, Anton Schmidt, also executive chairman of Ethicon Germany (a Johnson & Johnson company), with the support of BVMed director general Joachim Schmitt, to steer a course through the storm. Faraz Kermani interviewed them jointly during this year's Berlin Capital Congress
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.